PICO Anticipation: A Critical Activity Ahead of JCA
The European Commission has recently announced that the first Joint Clinical Assessment (JCA) is finalised and undergoing final checks prior
The #1 Biotech Misconception About Market Access: “A Partner Will Handle It”
“We don’t need to worry about Market Access, once we find a partner, they’ll take care of it.” It is
2026 Most-Favoured-Nation Playbook: Everything We Know About the Bilateral Drug Pricing Deals
In less than twelve months, the Trump administration turned a contested policy idea into a structural reality across the pharmaceutical
CMS GUARD Model 2026: A Complete Guide for Pharma and Biotech
December 2025 marked a defining moment in U.S. drug pricing and Medicare reimbursement policy. Alongside the GLOBE Model for Medicare
Understanding CMS’s GLOBE Model in 2026: What Pharma and Biotech Need to Know
December 2025 marked a pivotal moment in U.S. drug pricing policy. The Global Benchmark for Efficient Drug Pricing (GLOBE) Model
MFN Pricing: Mitigation Strategies for Pharma Companies in 2026
Most Favoured Nation (MFN) pricing policies are increasingly shaping global pharmaceutical launch, pricing, and access strategies. As MFN concepts link